We recently published a list of 10 Stocks That Will Profit From AI. In this article, we are going to take a look at where ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

Former House Speaker Nancy Pelosi's stock portfolio has taken a major hit in 2025, aligning with the broader market sell-off.

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong revenue growth. Read why TEM stock is a hold.

Tempus AI started off the year with a stellar ... a 79% YoY growth, bolstered by the Ambry Genetics acquisition and a rapidly growing TAM. Despite the deep selloff recently, I rank TEM a 'Strong ...

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...

Deep 6’s advanced algorithms complement Tempus AI’s existing platform, strengthening its foothold in AI-driven healthcare. The February 2025 acquisition of Ambry Genetics further expanded its ...

Other Strategic Acquisitions and Partnerships to Accelerate Growth The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus AI’s genomics capabilities by adding ...

For the full year, the Data and Services division was a key contributor. The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a ...